Cyclosporine: From renal transplantation to autoimmune diseases

Annals of the New York Academy of Sciences

Volumn 1051, Issue , 2005, Pages 551-558

  Ponticelli, Claudio ^a,b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b NONE   (Italy)

Author keywords

Autoimmune diseases; Cyclosporine; Cyclosporine nephrotoxicity; Renal transplantation

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AZATHIOPRINE; BARBITURIC ACID; BASILIXIMAB; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CIPROFLOXACIN; CLARITHROMYCIN; CREATININE; CYCLOSPORIN A; DACLIZUMAB; DILTIAZEM; ERYTHROMYCIN; EVEROLIMUS; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; STEROID; SULFONAMIDE; TACROLIMUS; UNINDEXED DRUG; VERAPAMIL;

ACUTE GRAFT REJECTION; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DRUG FORMULATION; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; META ANALYSIS; MICROEMULSION; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PSORIASIS; RHEUMATOID ARTHRITIS; RISK; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UVEITIS;

EID: 25444519959     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1361.099     Document Type: Conference Paper

References (47)

1. RENNIE, D. 1978. Home dialysis and the costs of uremia N. Engl. J. Med. 298: 399-400.
2. CALNE, R. 2004. Cyclosporine as a milestone in immunosuppression Transplant. Proc. 36 (Suppl. 2S9): 13S-15S.
3. CALNE, R.Y., K. ROLLES, D.J.G. WHITE, et al. 1978. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreas, and 2 livers. Lancet 2: 1033-1036.
4. EUROPEAN MULTICENTRE TRIAL GROUP. 1983. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 2: 986-989.
5. CANADIAN MULTICENTER TRANSPLANT STUDY GROUP. 1983. A randomized clinical trial of cyclosporine in cadaveric renal transplantation N. Engl. J. Med. 309: 809-815.
6. RUIZ-ORTEGA, M. & J. EGIDO. 1997. Angiotensin II modulates cell growth-related events and synthesis of matrix protein in renal interstitial fibroblasts. Kidney Int. 52: 1497-1510.
7. CHANDER, V. & K. CHOPRA. 2005. Effect of molsidomine and 1-arginine in cyclosporine nephrotoxicity: role of nitric oxide. Toxicology 207: 463-474.
8. SCHERRER, U., S.F. VISSING, B.J. MORGAN, et al. 1990. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N. Engl. J. Med. 323: 693-699.
9. SMITH, S.R., E.A. CREECH, A.V. SCHAFFER, et al. 1992. Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity Kidney Int. 41: 199-205.
10. RAMIREZ, C., A. OLMO, F. O'VALLE, et al. 2000. Role of intrarenal endothelin 1, endothelin 3, and angiotensin II expression in chronic cyclosporin A nephrotoxicity in rats. Exp. Nephrol. 8: 161-172.
11. XUE, H., R.D. BULOSKI, D.A. MC CARRON, et al. 1987. Induction of contraction in isolated rat aorta. Transplantation 43: 715-718.
12. LUKE, R.G. 1991. Mechanism of cyclosporine-induced hypertension. Am. J. Hypertens. 4: 468-471.
13. MIHATSCH, M.J., B. RYFFEL & F. GUDAT. 1995. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int. 48 (Suppl. 52): S63-69.
14. MIHATSCH, M.J., K. MOROZUMI, E.H. STROM, et al. 1995. Renal transplant morphology after long-term therapy with cyclosporine. Transplant. Proc. 27: 39-42.
15. MOROZUMI, K., A. TAKEDA, K. UCHIDA, et al. 2004. Cyclosporine nephrotoxicity how does it affect renal allograft function and transplant morphology? Transplant. Proc. 36 (Suppl. 2): 216-256.
16. BENNETT, W.M., A. DE MATTOS, M.M. MEYER, et al. 1996. Chronic cyclosporine nephropathy: the Achille's heel of immunosuppressive therapy. Kidney Int. 50: 1089-1100.
17. OPELZ, G. & B. DOHLER. 2001. Cyclosporine and long-term kidney graft survival. Transplantation 72: 1267-1273.
18. THERVET, E., E. MORELON, D. DUCLOUX, et al. 2000. Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion. Clin. Transplant. 14: 561-566.
19. PONTICELLI, C., G. CIVATI, A. TARANTINO, et al. 1996. Randomized study with cyclosporine in kidney transplantation: 10 year follow-up. J. Am. Soc. Nephrol. 7: 792-797.
20. LINDHOLM, A. & B.D. KAHAN. 1993. Influence of cyclosporine pharmacokinetics through concentrations and AUC monitoring on outcome after kidney transplantation. Clin. Pharmacol. & Ther. 54: 205-218.
21. MUELLER, E.A., J.M. KOVARIK, J.B. VAN BREE, et al. 1991. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm. Res. 11: 301-304.
22. KOVARIK, J.M., E.A. MUELLER, J.B. VAN BREE, et al. 1994.Reduced inter- and intra-individual variability in cyclosporine pharmacokinetics from a microemulsion formulation J. Pharmacol. Sci. 83: 444-446
23. SHAH, M.B., J.E. MARTIN, T.J. SCHROEDER, et al. 1999. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral. Transplant. Proc. 8: 4048-4053.
24. MEIER-KRIESCHE, H.U. & B. KAPLAN. 2002. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. Am. J. Transplant. 2: 100-104.
25. WOLFE, R.A., V.B. ASHBY, E.L. MILFORD, et al. 1999. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant N. Engl. J. Med. 341: 1725-1730.
26. HARIHARAN, S., C.P. JOHNSON, B.A. BRESNAHAN, et al. 2000. Improved graft survival after renal transplantation in the United States. N. Engl. J. Med. 342: 605-612.
27. PONTICELLI, C., M. VILLA, B. CESANA, et al. 2002. Risk factors for late kidney allograft failure. Kidney Int. 62: 1848-1852.
28. PONTICELLI, C., A. AROLDI, A. ELLI, et al. 1999. The clinical status of cadaveric renal transplant patients treated for 10 years with cyclosporine therapy. Clin. Transplant. 4: 324-329.
29. LEVY, G.A. 2004. Neoral C2 monitoring in solid organ transplantation. Transplant. Proc. 36 (Suppl. 2): 392S-395S.
30. DI PAOLO, S., A. TEUTONICO, A. SCHENA, et al. 2004. Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: results at 3 years. Am. J. Kidney Dis. 44: 886-892.
31. NANKIVELL, B.J., R.J. BORROWS, C.L. FUNG, et al. 2004. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78: 557-565.
32. KEOWN, P. 2004. Composite outcomes in renal transplantation using cyclosporine. Transplant. Proc. 36 (Supp.l 2): 35S-39S.
33. PONTICELLI, C. 2001. Steroid free immunosuppression. Transplant. Proc. 33: 3259-3260.
34. PASCUAL, M., T. THERUVATH, T. KAWAI, et al. 2002. Strategies to improve long-term outcomes after renal transplantation. N. Engl. J. Med. 346: 580-590.
35. KAHAN, B.D. & C. PONTICELLI. 2000. Immunosuppressive drugs: molecular and cellular mechanisms of action. In Principles and Practice of Renal Transplantation. B.D. Kahan and C. Ponticelli, Eds.: 315-345. Martin Dunitz. London.
36. GRIFFITHS, C.E., L. DUBERTRET, C.N. ELLIS, et al. 2004. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br. J. Dermatol. 150 (Suppl. 67): 11-23.
37. BUNIKOWSKI, R., D. STAAB, F. KUSSELEI, et al. 2004. Low-dose cyclosporine A microemulsion in children with severe atopic dermatitis. Clinical and immunological effects. Pediatr. Allergy Immunol. 4: 216-223.
38. GREMESE, E. & G.F. FERRACCIOLI. 2004. Benefit/risk of cyclosporine in rheumatoid arthritis. Clin. Exp. Rheumatol. 5 (Suppl. 35): 101-107.
39. SONG, J. Systemic management of posterior uveitis. 2003. J. Ocul. Pharmacol. Ther. 19: 325-343.
40. WALLACE, D.J. 2002. Management of lupus erythematosus: recent insights. Curr. Opin. Rheumatol. 3: 212-219.
41. VOTE, B.J., A. HALL, J. CAIRNS, et al. 2004. Changing trends in sympathetic ophtalmia. Clin. Exp. Ophtalmol. 32: 545-545.
42. PONTICELLI, C. & P. PASSERINI. 1999. The place of cyclosporine in the management of primary nephrotic syndrome. Biodrugs 12: 327-341.
43. PALESTINE, A.G., H.A. AUSTIN, III, J.E. BALOW, et al. 1986. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N. Engl. J. Med. 314: 1293-1298.
44. ZACHARIE, H., K. KRAGBALLE, H.E. HANSEN, et al. 1997. Renal biopsy findings in long-term cyclosporine treatment of psoriasis. Br. J. Dermatol. 136: 531-535.
45. FEUTREN, G. & M.J. MIHATSCH. 1992. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N. Engl. J. Med. 326: 1654-1660.
46. RODRIGUEZ, F., J.C. KRAYENBUHL, W.B. HARRISON, et al. 1996. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporine A. An update from the International Kidney Biopsy Registry. Arthritis Rheum. 39: 1491-1498.
47. PONTICELLI, C. 2004. Renal transplantation. Where do we stand today? Nephrol. Dial. Transplant. 12: 2937-2947.